alectinib + atezolizumab

A combination therapy consisting of alectinib, a highly selective ALK inhibitor, and atezolizumab, a PD-L1 inhibitor. Alectinib targets the anaplastic lymphoma kinase (ALK), which drives tumor growth in some cases of non-small cell lung cancer (NSCLC). Atezolizumab is a monoclonal antibody that blocks PD-L1, preventing it from binding to PD-1 receptors on T cells, thereby enhancing T-cell activation and anti-tumor immune responses. The combination aims to leverage both targeted therapy and immunotherapy mechanisms to potentially enhance efficacy beyond what either agent could achieve alone.

Brand names

TecentriqAlecensa

Other names

atezolizumab + alectinibTecentriq + Alecensa